Matricellular proteins: Extracellular modulators of cell function

Current Opinion in Cell Biology

Volumn 14, Issue 5, 2002, Pages 608-616

  Bornstein, Paul ^a   Sage, E Helene ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b HOPE HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CELL SURFACE RECEPTOR; COLLAGEN FIBRIL; CYTOKINE; GROWTH FACTOR; OSTEONECTIN; OSTEOPONTIN; PLATELET DERIVED GROWTH FACTOR; PROTEINASE; TENASCIN; THROMBOSPONDIN 1; THROMBOSPONDIN 2; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; APOPTOSIS; CELL ADHESION; CELL FUNCTION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CELL ULTRASTRUCTURE; CHEMOTAXIS; EXTRACELLULAR MATRIX; HOMEOSTASIS; HUMAN; HUMAN CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SPECIES DIFFERENCE; TUMOR GROWTH;

ANIMALIA; VERTEBRATA;

EID: 0036775425     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-0674(02)00361-7     Document Type: Review

References (70)

1. Carragher N.O., Levkau B., Ross R., Raines E.W. Degraded collagen fragments promote rapid disassembly of smooth muscle focal adhesions that correlates with cleavage of pp125(FAK), paxillin, and talin. J Cell Biol. 147:1999;619-629.
2. Bornstein P. Diversity of function is inherent in matricellular proteins: An appraisal of thrombospondin 1. J Cell Biol. 130:1995;503-506.
3. Bornstein P. Thrombospondins as matricellular modulators of cell function. J Clin Invest. 107:2001;929-934. This paper provides the first clear enunciation of the matricellular concept as it is used in this review.
4. Sage E.H., Bornstein P. Minireview: extracellular proteins that modulate cell-matrix interactions: SPARC, tenascin, and thrombospondin. J Biol Chem. 266:1991;14831-14834.
5. Lau L.F., Lam S.T. The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res. 248:1999;44-57.
6. Mao J.R., Taylor G., Dean W.B., Wagner D.R., Afzal V., Lotz J.C., Rubin E.M., Bristow J. Tenascin-X deficiency mimics Ehlers-Danlos syndrome in mice through alteration of collagen deposition. Nat Genet. 30:2002;1-5.
7. Bornstein P., Armstrong L.C., Hankenson K., Kyriakides T.R., Yang Z. Thrombospondin 2, a matricellular protein with diverse functions. Matrix Biol. 19:2000;557-568.
8. Brekken R.A., Sage E.H. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 19:2000;816-827.
9. Rittling S.R., Denhardt D.T. Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp Nephrol. 7:1999;103-113.
10. Giachelli C.M., Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol. 19:2000;615-622.
11. Jones P.L., Jones F.S. Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol. 19:2000;581-596.
12. Adams J.C. Thrombospondins: multifunctional regulators of cell interactions. Annu Rev Cell Dev Biol. 17:2001;25-51. This is a comprehensive, up-to-date review of thrombospondins.
13. Chen H., Herndon M.E., Lawler J. The cell biology of thrombospondin-1. Matrix Biol. 19:2000;597-614.
14. Lawler J. The functions of thrombospondin-1 and -2. Curr Opin Cell Biol. 12:2000;634-640.
15. Murphy-Ullrich J.E. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J Clin Invest. 107:2001;785-790. This paper postulates and provides evidence for an intermediate state of adhesion, which can be induced by a number of matricellular proteins and can account for some of the effects of these proteins on cells.
16. Goicoechea S., Orr A.W., Pallero M.A., Eggleton P., Murphy-Ullrich J.E. Thrombospondin mediates focal adhesion disassembly through interactions with cell surface calreticulin. J Biol Chem. 275:2000;36358-36368.
17. Hohenester E., Maurer P., Timpl R. Crystal structure of a pair of follistatin-like and EF-hand calcium-binding domains in BM-40. EMBO J. 16:1997;3778-3786.
18. Huang W., Chiquet-Ehrismann R., Moyano J.V., Garcia-Pardo A., Orend G. Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res. 61:2001;8586-8594.
19. Cukierman E., Pankov R., Stevens D.R., Yamada K.M. Taking cell-matrix adhesions to the third dimension. Science. 294:2001;1708-1712. This technically elegant paper emphasizes the importance of studying the interactions of the extracellular matrix with mesenchymal cells in a three-dimensional environment.
20. Yang Z., Kyriakides T.R., Bornstein P. Matricellular proteins as modulators of cell-matrix interactions: the adhesive defect in thrombospondin 2-null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2. Mol Biol Cell. 11:2000;3353-3364.
21. Yang Z., Strickland D.K., Bornstein P. Extracellular MMP2 levels are regulated by the LRP scavenger receptor and thrombospondin 2. J Biol Chem. 276:2001;8403-8408.
22. Agah A, Kyriakides TR, Lawler J, Bornstein P: The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double TSP1/TSP2-null mice. Am J Pathol 2002, in press
23. Kyriakides T.R., Zhu Y.-H., Yang Z., Huynh G., Bornstein P. Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of TSP2-null mice. Am J Pathol. 159:2001;1255-1262.
24. Pepper M.S. Extracellular proteolysis and angiogenesis. Thromb Haemost. 86:2001;346-355.
25. Mansfield P.J., Suchard S.J. Thrombospondin promotes chemotaxis and haptotaxis of human peripheral blood monocytes. J Immunol. 153:1994;4219-4229.
26. Huynh M.-H., Sage E.H., Ringuette M. A calcium-binding motif in SPARC/osteonectin inhibits chordomesoderm cell migration during Xenopus gastrulation: evidence of counteradhesive activity in vivo. Dev Growth Differ. 41:1999;407-418.
27. Bradshaw A.D., Sage E.H. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest. 107:2001;1049-1054. This review is current and emphasizes findings with SPARC-null mice.
28. Rempel S.A., Golembieski W.A., Fisher J.L., Maile M., Nakeff A. SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. J Neurooncol. 53:2001;149-160. This paper utilizes inducible expression of SPARC in glioma cell lines to show that SPARC affects tumor-cell adhesion and proliferation in a substrate-specific manner.
29. Bradshaw A.D., Reed M.J., Sage E.H. SPARC-null mice exhibit accelerated cutaneous wound closure. J Histochem Cytochem. 50:2002;1-10.
30. Bradshaw A.D., Reed M.J., Sage E.H. SPARC-null mice display enhanced fibrovascular invasion of subcutaneous sponge implants. Wound Repair Regen. 9:2002;522-530.
31. Danen E.J., Yamada K.M. Fibronectin, integrins, and growth control. J Cell Physiol. 189:2001;1-13. An excellent review of current literature, with novel ideas on integrins and growth factor co-signaling.
32. Cheresh D.A., Stupack D.G. Integrin-mediated death: an explanation of the integrin-knockout phenotype? Nat Med. 8:2002;193-194.
33. Kyriakides T.R., Zhu Y.-H., Smith L.T., Bain S.D., Yang Z., Li M.T., Danielson K.G., Iozzo R.V., LaMarca M., McKinney C.E., et al. Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J Cell Biol. 140:1998;419-430.
34. Bornstein P., Kyriakides T.R., Yang Z., Armstrong L.C., Birk D.E. Thrombospondin 2 modulates collagen fibrillogenesis and angiogenesis. J Invest Dermatol Symp Proc. 5:2000;61-66.
35. Delany A.M., Amling M., Priemel M., Howe C., Baron R., Canalis E. Osteopenia and decreased bone formation in osteonectin-deficient mice. J Clin Invest. 105:2000;915-923.
36. Francki A., Bradshaw A.D., Bassuk J., Howe C., Couser W., Sage E.H. SPARC regulates the expression of collagen type I and TGF-β1 in mesangial cells. J Biol Chem. 274:1999;32145-32152.
37. Yan Q., Clark J.I., Wight T., Sage E.H. Alterations in the lens capsule contribute to cataractogenesis in SPARC-null mice. J Cell Sci. 115:2002;2747-2756. The authors identify a mechanism for cataract formation in SPARC-null mice: a basement membrane (lens capsule) that is more permeable to water and small molecules.
38. Schwartz M.A. Integrin signaling revisited. Trends Cell Biol. 11:2001;466-470. A well written update on pathways and signaling networks involving integrins.
39. Bradshaw A.D., Francki A., Motamed K., Howe C., Sage E.H. Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and proliferation rates relative to wild-type cells. Mol Biol Cell. 10:1999;1569-1579.
40. Motamed K., Funk S.E., Raines E., Ross R., Sage E.H. Interaction of SPARC with human vascular smooth muscle cells: abrogation of mitogen-stimulated proliferation. J Cell Biochem. 84:2002;759-771. The authors provide data on specific components of the cell cycle that are affected by SPARC, and show that SPARC binds to smooth muscle cells.
41. Yiu G.K., Chan W.Y., Ng S.W., Chan P.S., Cheung K.K., Berkowitz R.S., Mok S.C. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol. 159:2001;609-622. This paper is the first indication that SPARC could influence tumor growth by its induction of apoptosis.
42. Denhardt D.T., Noda M., O'Regan A.W., Pavlin D., Berman J.S. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 107:2001;1055-1061. A current review on the biology of osteopontin, with emphasis on inflammation and apoptosis.
43. Lin Y.-H., Yang-Yen H.-F. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem. 276:2001;46024-46030.
44. Rodriguez-Manzaneque J.C., Lane T.F., Ortega M.A., Hynes R.O., Lawler J., Iruela-Arispe M.L. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA. 98:2001;12485-12490.
45. Dawson D.W., Bouck N.P. Thrombospondin as an inhibitor of angiogenesis. Teicher B.A., Antiangiogenic Agents in Cancer Therapy. 1999;185-203 Humana Press, Inc, Totowa, NJ.
46. Jimenez B., Volpert O.V., Crawford S.E., Febbraio M., Silverstein R.L., Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med. 6:2000;41-48.
47. Jimenez B., Volpert O.V., Reiher F., Chang L., Munoz A., Karin M., Bouck N. c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1. Oncogene. 20:2001;3443-3448.
48. Volpert O.V., Zaichuk T., Zhou W., Reiher F., Ferguson T.A., Stuart P.M., Amin M., Bouck N.P. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med. 8:2002;349-357.
49. Armstrong L.C., Björkblom B., Hankenson K.D., Siadak A.W., Stiles C., Bornstein P. Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol Biol Cell. 13:2002;1893-1905. This paper demonstrates that, in addition to their ability to cause apoptosis of endothelial cells, thrombospondins can also inhibit cell-cycle progression.
50. Wakefield L.M., Roberts A.B. TGF-β signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 12:2002;22-29.
51. Murphy-Ullrich J.E., Poczatek M. Activation of latent TGF-β by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev. 11:2000;59-69.
52. Crawford S.E., Stellmach V., Murphy-Ullrich J.E., Ribeiro S.M.F., Lawler J., Hynes R.O., Boivin G.P., Bouck N. Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell. 93:1998;1159-1170.
53. Miao W.-M., Seng W.L., Duquette M., Lawler P., Laus C., Lawler J. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res. 61:2001;7830-7839.
54. Abelouahed M., Ludlow A., Brunner G., Lawler J. Activation of platelet-transforming growth factor β-1 in the absence of thrombospondin-1. J Biol Chem. 275:2000;17933-17936.
55. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
56. Hogg P.J. Thrombospondin 1 as an enzyme inhibitor. Thromb Haemost. 72:1994;787-792.
57. Streit M., Riccardi L., Velasco P., Brown L.F., Hawighorst T., Bornstein P., Detmar M. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA. 96:1999;14888-14893.
58. Hawighorst T., Velasco P., Streit M., Hong Y.-K., Kyriakides T.R., Brown L.F., Bornstein P., Detmar M. Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J. 20:2001;2631-2640. This paper identifies the increased expression of thrombospondin 2 in stromal cells during chemical carcinogenesis, and the subsequent inhibition of angiogenesis, as important factors in the limitation of tumor growth.
59. Taraboletti G., Morbidelli L., Donnini S., Parenti A., Granger H.J., Giavazzi R., Ziche M. The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. FASEB J. 14:2000;1674-1676.
60. Chandrasekaran L., He C.-Z., Al-Barazi H., Krutzsch H.C., Iruela-Arispe M.L., Roberts D.D. Cell contact-dependent activation of α3β1 integrin modulates endothelial cell responses to thrombospondin-1. Mol Biol Cell. 11:2000;2885-2900.
61. Sage E.H. Pieces of eight: bioactive fragments of extracellular proteins as regulators of angiogenesis. Trends Cell Biol. 7:1997;182-186.
62. Agnihotri R., Crawford H.C., Haro H., Matrisian L.M., Havrda M.C., Liaw L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem. 276:2001;28261-28267.
63. Marneros A.G., Olsen B.R. The role of collagen-derived proteolytic fragments in angiogenesis. Matrix Biol. 20:2001;337-345.
64. 2+ in rat experimental wounds. J Clin Invest. 92:1993;2368-2376.
65. Grzeszkiewicz T.M., Kirschling D.J., Chen N.Y., Lau L.F. CYR61 stimulates human skin fibroblast migration through integrin alpha(V)beta(5) and enhances mitogenesis through integrin alpha(V)beta(3), independent of its carboxyl- terminal domain. J Biol Chem. 276:2001;21943-21950.
66. Inoki I., Shiomi T., Hashimoto G., Enomoto H., Nakamura H., Makino K., Ikeda E., Takata S., Kobayashi K., Okada Y. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 15:2001;U393-U419.
67. Lawler J., Sunday M., Thibert V., Duquette M., George E.L., Rayburn H., Hynes R.O. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest. 101:1998;982-992.
68. Yoshitake H., Rittling S.R., Denhardt D.T., Noda M. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci USA. 96:1999;8156-8160.
69. Mackie E.J., Tucker R.P. The tenascin-C knockout revisited. J Cell Sci. 112:1999;3847-3853.
70. Matsumoto K., Takayama N., Ohnishi J., Ohnishi E., Shirayoshi Y., Nakatsuji N., Ariga H. Tumour invasion and metastasis are promoted in mice deficient in tenascin-X. Genes Cells. 6:2001;1101-1111.